239 related articles for article (PubMed ID: 29910009)
1. Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: A double-blind randomized clinical trial in Singapore.
Guo S; Manning V; Yang Y; Koh PK; Chan E; de Souza NN; Assam PN; Sultana R; Wijesinghe R; Pangjaya J; Kandasami G; Cheok C; Lee KM; Wong KE
J Subst Abuse Treat; 2018 Aug; 91():1-11. PubMed ID: 29910009
[TBL] [Abstract][Full Text] [Related]
2. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.
Gorodetzky CW; Walsh SL; Martin PR; Saxon AJ; Gullo KL; Biswas K
Drug Alcohol Depend; 2017 Jul; 176():79-88. PubMed ID: 28527421
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial.
Fishman M; Tirado C; Alam D; Gullo K; Clinch T; Gorodetzky CW;
J Addict Med; 2019; 13(3):169-176. PubMed ID: 30531234
[TBL] [Abstract][Full Text] [Related]
4. A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
Yu E; Miotto K; Akerele E; Montgomery A; Elkashef A; Walsh R; Montoya I; Fischman MW; Collins J; McSherry F; Boardman K; Davies DK; O'Brien CP; Ling W; Kleber H; Herman BH
Drug Alcohol Depend; 2008 Sep; 97(1-2):158-68. PubMed ID: 18508207
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine for managing opioid withdrawal.
Gowing L; Ali R; White JM; Mbewe D
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD002025. PubMed ID: 28220474
[TBL] [Abstract][Full Text] [Related]
7. Alpha₂-adrenergic agonists for the management of opioid withdrawal.
Gowing L; Farrell M; Ali R; White JM
Cochrane Database Syst Rev; 2016 May; 2016(5):CD002024. PubMed ID: 27140827
[TBL] [Abstract][Full Text] [Related]
8. Lofexidine, an {alpha}2-receptor agonist for opioid detoxification.
Gish EC; Miller JL; Honey BL; Johnson PN
Ann Pharmacother; 2010 Feb; 44(2):343-51. PubMed ID: 20040696
[TBL] [Abstract][Full Text] [Related]
9. Alpha2-adrenergic agonists for the management of opioid withdrawal.
Gowing L; Farrell MF; Ali R; White JM
Cochrane Database Syst Rev; 2014 Mar; (3):CD002024. PubMed ID: 24683051
[TBL] [Abstract][Full Text] [Related]
10. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J
Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857
[TBL] [Abstract][Full Text] [Related]
11. Lofexidine versus clonidine in rapid opiate detoxification.
Gerra G; Zaimovic A; Giusti F; Di Gennaro C; Zambelli U; Gardini S; Delsignore R
J Subst Abuse Treat; 2001 Jul; 21(1):11-7. PubMed ID: 11516922
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.
Walsh SL; Strain EC; Bigelow GE
Addiction; 2003 Apr; 98(4):427-39. PubMed ID: 12653813
[TBL] [Abstract][Full Text] [Related]
13. Opioid antagonists with minimal sedation for opioid withdrawal.
Gowing L; Ali R; White JM
Cochrane Database Syst Rev; 2017 May; 5(5):CD002021. PubMed ID: 28553701
[TBL] [Abstract][Full Text] [Related]
14. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.
Sinha R; Kimmerling A; Doebrick C; Kosten TR
Psychopharmacology (Berl); 2007 Mar; 190(4):569-74. PubMed ID: 17136399
[TBL] [Abstract][Full Text] [Related]
15. Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review.
Kuszmaul AK; Palmer EC; Frederick EK
J Am Pharm Assoc (2003); 2020; 60(1):145-152. PubMed ID: 31791720
[TBL] [Abstract][Full Text] [Related]
16. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital.
Kahn A; Mumford JP; Rogers GA; Beckford H
Drug Alcohol Depend; 1997 Jan; 44(1):57-61. PubMed ID: 9031821
[TBL] [Abstract][Full Text] [Related]
17. Lofexidine (Lucemyra) for Treatment of Opioid Withdrawal Symptoms.
Bryce C
Am Fam Physician; 2019 Mar; 99(6):392-394. PubMed ID: 30874408
[No Abstract] [Full Text] [Related]
18. The effectiveness of combined naloxone/lofexidine in opiate detoxification: results from a double-blind randomized and placebo-controlled trial.
Beswick T; Best D; Bearn J; Gossop M; Rees S; Strang J
Am J Addict; 2003; 12(4):295-305. PubMed ID: 14504022
[TBL] [Abstract][Full Text] [Related]
19. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal.
Carnwath T; Hardman J
Drug Alcohol Depend; 1998 May; 50(3):251-4. PubMed ID: 9649979
[TBL] [Abstract][Full Text] [Related]
20. Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal.
Doughty B; Morgenson D; Brooks T
Ann Pharmacother; 2019 Jul; 53(7):746-753. PubMed ID: 30724094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
